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Abstract The New York Consortium on Membrane
Protein Structure (NYCOMPS), a part of the Protein
Structure Initiative (PSI) in the USA, has as its mission to
establish a high-throughput pipeline for determination of
novel integral membrane protein structures. Here we
describe our current target selection protocol, which
applies structural genomics approaches informed by the
collective experience of our team of investigators. We ﬁrst
extract all annotated proteins from our reagent genomes,
i.e. the 96 fully sequenced prokaryotic genomes from
which we clone DNA. We ﬁlter this initial pool of
sequences and obtain a list of valid targets. NYCOMPS
deﬁnes valid targets as those that, among other features,
have at least two predicted transmembrane helices, no
predicted long disordered regions and, except for com-
munity nominated targets, no signiﬁcant sequence simi-
larity in the predicted transmembrane region to any known
protein structure. Proteins that feed our experimental
pipeline are selected by deﬁning a protein seed and
searching the set of all valid targets for proteins that are
likely to have a transmembrane region structurally similar
to that of the seed. We require sequence similarity aligning
at least half of the predicted transmembrane region of seed
and target. Seeds are selected according to their feasibility
and/or biological interest, and they include both centrally
selected targets and community nominated targets. As of
December 2008, over 6,000 targets have been selected and
are currently being processed by the experimental pipeline.
We discuss how our target list may impact structural
coverage of the membrane protein space.
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Introduction
NYCOMPS as part of the PSI
The protein structure initiative (PSI) is the leadingstructural
genomics (SG) initiative in the USA; it is funded by the
National Institute of General Medical Sciences (NIGMS) at
the National Institutes of Health (NIH). The PSI currently
supports four large production centers and six specialized
centers as well as other activities [1–3]. Two of these spe-
cialized centers focus on developing new technologies for
membrane protein structure determination: the Center
for Structures of Membrane Proteins (CSMP) [4] and the
New York Consortium on Membrane Protein Structure
(NYCOMPS). At NYCOMPS (http://www.nycomps.org/)
we have established a high-throughput pipeline beginning
with target selection and further including protein puriﬁca-
tion, protein expression and scale-up. Scaled-up proteins are
sent to individual participating labs (within or outside of the
consortium)forstructuredeterminationtrials.Whilemostof
our resources are channeled into X-ray crystallography, we
also pursue structure determination by NMR, solid-state
NMR and cryo-electron microscopy. Here, we describe
target selection, the ﬁrst stage of the NYCOMPS pipeline.
Structure determination of integral membrane proteins
is difﬁcult
Integral membrane proteins (IMPs) are usually classiﬁed
into two structural classes, according to the secondary
structure conformation adopted by their membrane span-
ning segments [5, 6]: alpha helical bundle integral mem-
brane proteins (aIMPs; estimated to constitute *25% of an
average proteome [7, 8]) and beta barrel IMPs (estimated,
for example, to account for *2–3% of proteins in Gram-
negative bacteria [9–11]). These two classes of proteins
differ also in their membrane localization: beta barrels are
exclusive to the outer membrane of Gram-negative bacte-
ria, atypical Gram-positive bacteria, mitochondria and
chloroplasts, while alpha helical IMPs have been observed
in all other membranes [12]. Recent structural data dem-
onstrates the existence of at least one additional structural
class of IMPs, the alpha barrel [13]. At NYCOMPS, we
have so far focused only on aIMPs, because of their
abundance in genomes and high biological and medical
relevance [6, 14].
aIMPs are among the most difﬁcult proteins for struc-
ture determination studies [15–17]. Consequently, they are
extremely under-represented in the set of proteins for
which we have high-resolution experimental structures. In
particular, fewer than 1% of the proteins in the Protein
Data Bank (PDB) [18] are IMPs (in March 2009 there are a
total of 432 IMPs including both aIMP and beta barrels
among the 56,217 PDB structures, see http://blanco.
biomol.uci.edu/Membrane_Proteins_xtal.html for up-to-
date IMPs statistics [19]) while estimates based on fully
sequenced genomes predict that 25% of all annotated
proteins are aIMPs [7, 8].
aIMPs present several challenges for successful exper-
imental structure determination. First, high protein yields
are often essential for structural studies; unfortunately,
aIMPs are generally expressed at naturally low levels and
their over-expression is often toxic to the cell [20]. Second,
aIMPs are usually insoluble due to the long hydrophobic
helices that are needed to span the lipid bilayer of the
membrane core (typically around 17 residues long [21,
22]). Detergents are used to disrupt the membrane and
prevent nonspeciﬁc aggregation. However, the choice of
the detergent and the optimization of other buffer compo-
nents, such as salt and glycerol, are challenging tasks [23,
24]. Finally, solution components that are useful for protein
solubilization can interfere with crystallization, and crys-
tallization success is also heavily dependent on the lipid
content of the protein–detergent complexes [17]. In
essence, each step in the experimental puriﬁcation and
structure determination of an aIMP is extremely demand-
ing; typically, many parameters must be optimized to
obtain a high-resolution membrane protein structure [15],
usually working with small amounts of proteins.
SG adds large sampling of diversity as a new dimension
Structural genomics (SG) tries to increase the odds of
experimentally obtaining high-resolution structures by
using a pan-genomic approach that adds homology as a
new dimension to the structure determination problem.
This approach has been described in numerous publications
[25–27]. Typically, all proteins within a given realm are
clustered into pan-genomic sequence families, i.e. families
with members found in different genomes, and then a set of
those proteins are selected for which DNA templates are
available from ‘reagent’ genomes. The set of proteins is
tested experimentally for structure determination. An
experimental structure for any one member of the family
can serve through comparative modeling to inform studies
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123on any other family member [28]. This rationale is behind
the tremendous success and impact of the PSI structural
leverage [29]. Here, we take a slightly different approach
based on the concept of seed sequences. In brief, given a
target protein p* (the ‘‘seed’’) our goal is to ﬁnd a protein
p, the structure of which is predicted to be similar to p* and
that surrenders a high-resolution structure using available
experimental procedures (whereas the seed may fail). As in
the conventional approach, the structure of p can provide a
comparative structural model for p*. The advantage of this
approach over clustering of the full set of targets at the
inception of the project is that we can create our families
by expanding promising seeds whenever such seeds
become available, instead of having to map these seeds to
predeﬁned families. This is likely to increase the ‘central-
ity’ of the seed with respect to the cluster.
Goals of target selection at NYCOMPS
The NYCOMPS target selection aims at providing the
experimental pipeline with aIMPs that are: (1) novel with
respect to what is already in the PDB, (2) diverse, with
respect to their known sequence, structural and functional
features, and (3) most likely to yield a structure. In order to
increase aIMP feasibility we apply several computational
ﬁlters that eliminate candidates less likely to succeed.
These ﬁlters range from the exclusion of proteins known to
constitute individual subunits of hetero-oligomeric com-
plexes to the removal of proteins predicted to have long
regions of disorder. Whatever passes those ﬁlters will enter
the experimental structure determination pipeline at the
New York Structural Biology Center. Targets pursued
experimentally by NYCOMPS fall mostly into two broad
categories: nominated and centrally selected targets. The
way these targets are selected and their potential signiﬁ-
cance for structural coverage of the aIMP sequence and
functional space is the subject of this contribution. We also
brieﬂy cover several special case targets that do not fall
into either of the previous two categories. The Results
section is organized into two parts: target selection (Task I)
and target analysis (Task II).
Our target selection protocol has constantly been
evolving since the start of NYCOMPS in fall 2005. The
protocol has been modiﬁed to accommodate comments and
suggestions coming from our team of investigators, as well
as from the NYCOMPS scientiﬁc advisory committee, the
NIH review panels and novel data that have appeared in the
literature. In the ﬁrst part of Results (target selection), we
describe the protocol as of January 2009, although a frac-
tion of the targets analyzed in the second part of Results
(target analysis) were selected according to older criteria
that did not include all the ﬁltering steps described here.
Materials and methods
Creation of the NYCOMPS98 dataset
RefSeq target sequences
We downloaded 96 prokaryotic genomes in their amino
acid sequence translation from the NCBI Reference
Sequence collection (RefSeq [30]; ftp://ftp.ncbi.nih.gov/
genomes; Table S1). 82 genomes are Bacteria (55 Gram-
and 26 Gram?, including 3 Gram? in the genus Myco-
plasma, plus one genome that belongs to the phylum of
Cyanobacteria), 14 are Archaea.N o t et h a ts o m eo ft h e
NYCOMPS targets described here belong to 19 additional
genomes that were retired in June 2008 because of: strain
mismatch between the RefSeq strain and the one provided
by the ATCC
 (the source of our genomic DNA), early
indications of poor cloning/expression performance from
our experimental pipeline or both. Note also that our active
list of genomes still comprises seven genomes for which we
currently do not have an exact strain match with the ATCC
provided genomic DNA or for which a match is uncertain.
These genomes were retained based on early indications
that, in these cases, strain mismatch was not causing major
problems at the cloning level. Overall, the 96 NYCOMPS
genomes encode 310,357 protein sequences.
Trasmembrane helix predictions
In order to identify aIMPs in the 96 chosen prokaryotic
genomes, we run TMHMM2 [31] on all sequences. While
TMHMM2 has been reported to be one of the best trans-
membrane helix (TMH) prediction programs in more than
one independent assessment [32, 33], it is also one of the
fastest, i.e. ideal for predicting TMHs on a large number of
sequences. TMHMM2 returns the number and location of
predicted TMHs in a sequence. In principle, all proteins
with at least one predicted TMH are predicted by
TMHMM2 to be aIMPs. To remain on the safe side, we
considered as valid targets only proteins with two or more
predicted TMHs.
Redundancy reduction
We run CD-HIT [34] with a 98% sequence identity
threshold (we used parameters: -n 5 -c 0.98 -l 30 -d 30) on
all proteins left from the previous step. This ensured that no
two proteins in our dataset shared more than 98% sequence
identity. When considering proteins sharing more than 98%
sequence identity, the decision on which one to retain in
our database depended on the genome the sequences
belonged to. In particular, we prioritized: (1) sequences
Target selection for integral membrane proteins 257
123from Archaea (following the guess of our team of experi-
mentalists that they may provide more stable proteins) and
from a list of best performing genomes (‘‘best’’ in terms
structure yield for globular soluble proteins) provided to us
by the Northeast Structural Genomics Consortium; this list
was later substituted by a list of genomes with best
expression yield based on preliminary data from our
experimental pipeline (data not shown); (2) the longest
sequence (i.e. as selected by CD-HIT).
Signal peptide predictions
We run SignalP [35] on all sequences from Bacteria left in
our list (note: no SignalP for sequences in Archaea is
available [35]), and excluded all sequences predicted to
have two TMHs but for which the ﬁrst predicted TMH
started before a predicted cleavage site. For the position of
the cleavage site, we took the maximum out of the neural
network and the HMM SignalP predictions.
Disorder predictions
We identiﬁed disordered residues in our sequences by
running IUPred [36] using the option ‘glob’ that predicts
structured domains in a protein. IUPred is one of the best
performing programs for prediction of long disordered
regions [37, 38] and it is also extremely fast. We discarded
all proteins that had more than 15 consecutive residues
predicted by IUPred not to be in a structured domain.
The sequences left after running this protocol constitute
what we call the NYCOMPS98 dataset (39,037 sequences
total).
Criterion for establishing evolutionary relationships
between aIMPs
In order to ﬁnd homologs of an aIMP query sequence, we
used sequence similarity. We run three iterations of PSI-
BLAST [39]: two proﬁle generating iterations of the query
against a large database composed of the sum of Uni-
ProtKB [40] and PDB [18], and one ﬁnal iteration on the
aIMP dataset of interest, e.g. TCDB [41] (parameters ﬁrst
two iterations: -j 3– v 1,000 –t 1- h 1e-10 -e 0.001 -FF ; last
iteration: -e 1– t 1– v 50,000 -b 50,000 -FF ). Note that we
input the ‘effective length of database’ of the ﬁrst iterations
into the last iteration (-z option) in order to have an esti-
mate of the alignments’ E values based on a large database.
We ﬁrst selected as ‘homologs’ of the query protein all
sequences that aligned to it with E value\10
-3 in the last
iteration. Then, we additionally required all retained
sequences to align to the query so that the alignment
covered at least 50% of the residues predicted to be in a
TMH in both query and subject sequence. All proteins that
satisﬁed these constraints were considered part of the same
structural family as the query sequence. Except when
otherwise indicated, this is the criterion used to establish
similarity between aIMPs throughout the paper.
Clustering of proteins in the ‘von Heijne list’
We clustered E. coli proteins in the ‘von Heijne list’ (613
protein total) using a variation of the CLUP algorithm [25,
42]. For establishing similarity between proteins, we used
the criterion described above. For clustering, we chose as
the initial seed the shortest protein in the list and then seeds
of increasing length until no sequences were left [25, 42].
Once the E. coli proteins were grouped into paralogous
clusters, we further merged any two clusters that had at
least one common member such that the whole region
aligned to the seed of the ﬁrst cluster was also aligned to
the seed of the second, or vice versa.
Post-seed-expansion ﬁltering of targets
Exclusion of protein sequences similar to those in the PDB
We run three iterations of PSI-BLAST [39] using the same
databases and parameters used for establishing evolution-
ary relationships between aIMPs (see above). Only dif-
ferences were the E value threshold we used and the
transmembrane (TM) coverage we required. Indeed, we
discarded all proteins that at any iteration aligned with E
value\1 to a PDB protein and for which the alignment
covered at least 25% of the residues predicted to be in a
TMH in the target protein. Note that in this case the frac-
tion of a PDB protein TM region aligned to the query was
not deemed relevant. Even in cases in which the alignment
extended over 100% of the TM region of a PDB protein,
the target was not discarded unless the alignment covered
more than 25% of the target TM region.
Exclusion of individual subunits of hetero-oligomeric
complexes
EcoCyc [43] is an annotated database for E. coli strain K-12
MG1655; Swiss-Prot [40, 44] is a general-purpose database
including proteins from thousands of different species. To
collect information about the possible role of a given protein
as constituent subunit of a hetero-oligomeric complex, we
queried EcoCyc manually for E. coli proteins and Swiss-Prot
automatically for both E. coli and non E. coli proteins. From
the Swiss-Prot searches we used information from the
‘‘FUNCTION’’, ‘‘INTERACTIONS’’, ‘‘SUBUNITS’’,
‘‘COFACTORS’’, ‘‘SUBCELLULAR LOCATION’’, ‘‘DIS-
EASE’’, ‘‘DOMAIN’’ and ‘‘SIMILARITY’’ ﬁelds. This data
wasthenmanuallyinspectedbyourteamofexperimentalists,
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123who were asked to take a decision on whether or not to
approve a given seed family.
Exclusion of seed family ‘outliers’
In this manual step, we excluded proteins that were very
different with respect to the seed in terms of length and
number of TMHs. What ‘very different’ meant depended
on the family under consideration but, in general, proteins
that had a difference of more than two predicted TMHs or
had long ([100 residues) insertions with respect to the seed
were prime candidates for exclusion. Also, we generally
excluded proteins whose N-terminus we suspected might
have been wrongly annotated. To this aim, we built a
multiple sequence alignment of the whole family using
CLUSTALW [45] and manually inspected all members’
N-terminal regions. If a consensus N-terminus could be
identiﬁed, sequences that aligned with the consensus but
displayed extra N-terminal residues were discarded.
Comparing NYCOMPS targets to Pfam-A
Pfam [46] is a large database of protein families. Here we
used the Pfam-A collection of ‘‘high quality, manually
curatedfamilies’’(10,340total,version23.0).Thesefamilies
may or may not correspond to domains [46, 47]. We run the
Pfam-provided program pfam_scan.pl on all selected target
sequences(usingthe‘‘-overlap’’optiontokeepallhitswithin
the same clan of families and default parameters). We con-
sidered all Pfam family hits below E value 10
-3,1 0
-10 or
10
-50 and additionally required the Pfam families to cover a
percentage of the target’s TM region equal to or higher than
25, 50, 75 or 100%. If more than one Pfam family matched
the target, we considered the overall coverage of the target
TM region provided by all matching Pfam families. For E
value\10
-3 and C50% coverage, we repeated the same
calculation this time requiring that it existed at least one
individual Pfam family providing the full 50% coverage of
the target TM region. This gave the 70% (of target proteins)
ﬁgure that we provide in the ‘‘Results’’ section. We addi-
tionally calculated annotated-only Pfam family hits by
excluding Domains of Unknown Function (DUFs) and
Uncharacterized Protein Families (UPFs).
Comparing NYCOMPS targets to TCDB
Transport Classiﬁcation Database (TCDB) [41] is a mem-
brane transport protein database based on the Transporter
Classiﬁcation system, which is analogous to the enzyme
commission (EC) system for enzyme classiﬁcation. Note
that TCDB includes both aIMPs and beta barrel integral
membrane proteins. For our analysis, we used the version
of the database from July 2008. TCDB is organized into 5
levels (each level identiﬁed by a number or a letter), rep-
resenting the transporter class (7 classes in the version that
we used), subclass (24), superfamily/family (557), sub-
family (1,320) and substrate transported (3,224) for a total
of 5,005 sequences. In order to estimate the fraction of
TCDB classes, subclasses and superfamilies/families cov-
ered by our targets (ﬁrst 3 levels of TCDB), we proceeded
as follows. We run 1,000 bootstrapping [48] iterations. At
each iteration, we picked at random exactly one target for
each seed family (to mimic the situation in which we solve
only one structure per seed family) and aligned all such
targets against TCDB. At the end of each iteration, we
calculated the number of different TCDB identiﬁers cov-
ered by our randomly picked targets (i.e. the number of
TCDB identiﬁers corresponding to TCDB proteins that
aligned to those targets). Finally, after 1,000 iterations, we
calculated the average and standard deviation of the per-
centage of TCDB numbers covered with respect to the total
(again, for the ﬁrst three levels in the classiﬁcation). We
repeated this operation considering only 25, 50 and 75% of
the seed families, selecting the families at random in each
iteration, without re-sampling.
Comparing NYCOMPS targets to UniProtKB
UniProtKB [44, 49] is a protein repository composed of the
manually annotated Swiss-Prot and of the automatically
annotated TrEMBL databases. Here, we only considered
UniProtKB proteins with at least 2 predicted TMH (Uni-
ProtKB-TMH). Since we wanted to calculate novel lever-
age [50] of the UniProtKB-TMH subset provided by
NYCOMPS targets, we ﬁrst had to calculate the leverage
on the same subset provided by aIMPs currently in the
PDB. In fact, UniProtKB-TMH proteins that show signif-
icant similarity to PDB proteins cannot be claimed as
‘‘novel leverage’’ by NYCOMPS targets. To ﬁnd aIMPs in
the PDB we considered all PDB sequences (February 2009)
and run TMHMM2 [31] on the entire set. We discarded all
sequences predicted to have less than 2 TMHs and reduced
redundancy at 98% sequence identity using CD-HIT [34]
(as done for the NYCOMPS targets). This left us with 187
proteins. We preferred this deﬁnition of aIMPs rather than
using the annotations provided by PDB because it more
closely reﬂected the way our target sequences were anno-
tated as aIMPs (i.e. using TMH prediction). Finally, we
aligned these sequences against UniProtKB-TMH and
labeled all sequence similar UniProtKB-TMH proteins as
‘not-novel’. Note that in this case criterion for similarity to
PDB proteins is as in Fig. 2. When calculating the Uni-
ProtKB-TMH leverage of our targets, we excluded all
proteins labeled as ‘not novel’ and performed bootstrap-
ping [48] to calculate averages and standard deviations in
the same way as described for TCDB. In the same way, we
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UniProtKB-TMH-Human. For comparison, we also calcu-
lated ratios between NYCOMPS target leverage and PDB
protein leverage by taking average leverage values obtained
from bootstrapping for NYCOMPS targets and leverage of
the just described 187-protein subset for PDB proteins.
Results and discussion
Task I: target selection
NYCOMPS98: creating a valid target list
of predicted alpha helical membrane proteins (Fig. 1a)
First, we chose from the RefSeq collection [30] 96 fully
sequenced prokaryotic genomes (Table S1) for which
genomic DNA was available from ATCC
 (total of 310,357
proteins). This choice was heavily inﬂuenced by the expe-
riences from the large-scale SG centers [1], in particular
from NESG, the Northeast Structural Genomics consortium
[51], and from NYSGXRC, the New York SGX Research
Center for Structural Genomics [52]. We predicted TMHs
for all genomic regions annotated as proteins. Overall, we
found that the average number of predicted TMHs in all 96
genomeswas24%.Thisconﬁrmedpreviousﬁndings[7,47].
Per genome percentages varied from 19% (Methanocaldo-
coccus jannaschii) to 30% (Clostridium perfringens; Fig.
S1). Among all membrane proteins that were predicted to
integrate helices into the membrane (referred to as aIMPs),
thosewithasinglehelix(singlespan)dominated(7.5%ofall
proteins) accounting for about one-third of all predicted
aIMPs, followed by aIMPs with 2 and 6 TMHs (Fig. S2).
Since most of our targets had no experimental annota-
tion linking them to the membrane, we had to rely on
prediction methods. Such methods are estimated to be very
accurate [32, 53], however, inevitably they will at times
make TMH prediction mistakes. For target selection, we
therefore only included proteins with C2 predicted TMHs.
After this, we reduced redundancy by ﬁltering out targets
with exceedingly similar sequences guaranteeing that no
two proteins in our dataset shared more than 98% pairwise
sequence identity. Indeed, while we welcomed redundancy,
we wanted to avoid cloning very similar proteins as very
Fig. 1 Target selection protocol at NYCOMPS. a Building the
NYCOMPS98 dataset of valid targets. We selected targets from 96
fully sequenced prokaryotic genomes. We used TMHMM2 [31]t o
predict TMHs in this set and retained only sequences with C2 TMHs.
Finally, we applied a series of additional ﬁlters: we reduced
redundancy at 98% using CD-HIT [34], we removed all sequences
with 2 predicted TMHs for which the ﬁrst TMH overlapped with a
predicted signal peptide (using SignalP [35]) and we discarded
sequences with at least 15 consecutive residues predicted to be
disordered (using IUPred [36]). All sequences left constitute our set of
valid targets, which we call NYCOMPS98. b Expanding a protein
seed into a family of related proteins within NYCOMPS98. The seed
is aligned against the whole NYCOMPS98 dataset using PSI-BLAST
[39]. Retained sequences are those that satisfy our similarity criterion
(Fig. 2). From this list we eliminate: sequences that are signiﬁcantly
similar to PDB proteins (ﬁlter is not applied to nominated targets),
sequences known to constitute individual subunits of hetero-oligo-
meric complexes and sequences that differ signiﬁcantly from the seed
with respect to sequence length and number of predicted TMHs. We
also discard proteins that align well with the family N-terminus
consensus sequence (if any such consensus can be identiﬁed) but add
some extra N-terminal residues, i.e. are possibly mis-annotated (Fig.
S3). All remaining sequences are ﬁnally sent to cloning
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123close homologs have been shown to have similar crystal-
lization propensities [54].
In order to further decrease the chance of introducing
water-soluble non-aIMPs into our pipeline, we also
excluded sequences with two predicted TMHs for which
the position of the most N-terminal TMH overlapped with
a predicted signal peptide (the most common mistake of
TMH prediction programs is to predict an N-terminal TMH
in place of a signal peptide [53]). Finally, we ﬁltered out
proteins that were predicted to have more than 15 con-
secutive disordered residues and hence might be prob-
lematic for crystallization [55]. The remaining sequences
constitute what we refer to as the NYCOMPS98 dataset
(39,037 aIMPs).
Cloning families (Fig. 1b)
The two principal steps in target selection are: (1) the
identiﬁcation of targets that constitute promising candi-
dates for structure determination and/or are of utmost
biological interest; we refer to these as to the ‘‘seeds’’. (2)
The expansion of the seeds into families of—usually
homologous—proteins likely to have membrane structures
similar to the seed; we expand the seeds considering only
sequences that are part of the NYCOMPS98 set of valid
targets. NYCOMPS seeds are chosen from two distinct
tracks that we refer to as ‘‘central selection’’ and ‘‘nomi-
nation’’. Centrally selected seeds (139 proteins) have so far
been selected according to prior indications of successful
over-expression in our E. coli host [56] (details below). In
contrast, nominated seeds (35 proteins) have been hand-
picked by participating and adjoined laboratories; most of
these seeds are well-studied proteins of known function.
Note that seeds do not need to be proteins within NY-
COMPS98 and not even within our collection of genomes.
A protein is a valid seed as long as we can ﬁnd homologs in
the NYCOMPS98 dataset and as long as these homologs
pass all the additional ﬁlters described below.
Central seed selection
In central seed selection our main concern was to pick
membrane proteins that were more likely to readily provide
high-resolution structures and that differed substantially in
sequence within the TM region from proteins for which
structures had already been determined experimentally.
Given the small number of membrane protein structures
available in the PDB, predictions as to which membrane
proteinsconstitutestructure-pronetargetscanatthemoment
rather be based on a misunderstanding of statistics than on
sustainablescience.Wethereforescaleddownourambitions
and started with proteins that were likely to give high yields
of expression in our E. coli host (eventually increasing the
odds to determine their structure). Such a list of proteins
became available at the outset of the project thanks to a
published genome-wide expression study performed on E.
coliproteins[56].Althoughthemaingoaloftheworkbyvon
Heijne and coworkers was to determine the localization of
the C-terminus of E. coli aIMPs (either inside the cell or in
the periplasm), an important side effect was to provide us
with a list of proteins that were successfully over-expressed
in E. coli. In fact, all 139 NYCOMPS seeds that have so far
beencentrallyselectedhavebeenextractedfromalistof613
proteins provided to us by Erik Granseth (Stockholm Uni-
versity,Sweden). NYCOMPSrefers to this set of proteins as
‘‘thevonHeijnelist’’(www.rostlab.org/punta/vonHeijnelist.
txt).Allproteinsinthislistweresuccessfullyover-expressed
inE.coliinfusionwithGFPorphosphataseA[56].Ourhope
had therefore been that expanding these proteins into our 96
reagent genomes would provide a longer list of ‘‘good
expressers’’, eventually increasing the odds for obtaining a
structure for each seed family.
The initial von Heijne list was not unique at the
sequence level; it included paralogs. Hence, we ﬁrst clus-
tered the proteins in the von Heijne list according to
sequence similarity (the clustering procedure was adapted
from methods described in references [25, 42], see
‘‘Methods’’ for more details). This resulted in 268 E. coli
paralogy groups. The protein with the highest ﬂuorescence
level in each group was then selected as seed for the
expansion into the NYCOMPS98 dataset (following prior
indications that ﬂuorescence levels correlated with
expression levels [57]). Several of these initial families
were subsequently excluded due to one or several of the
following reasons: (1) they were similar to membrane
proteins of known structure (i.e. in the PDB; note, how-
ever, that for a handful of centrally selected seeds now
exists a structure of a homolog in the PDB that was
deposited after the seed was selected), (2) they represented
isolated subunits of hetero-oligomeric complexes, (3) they
had less than 5 homologs in the entire UniProtKB [44, 49];
i.e. they provided low structural leverage). Some of the
largest families (hundreds of homologs in NYCOMPS98)
have also been held back, waiting for a data-driven crite-
rion that could allow us to select only a fraction of
homologs among all those available for the family; a cri-
terion that would, for example, allow us to select proteins
that we predict to express well under our experimental
protocol. To date, 139 seeds from the von Heijne list have
been selected for cloning.
Nominated seed selection
Nominated seeds (handpicked by participating groups) are
special in many respects. For one, novelty with respect to
PDB proteins is not enforced. Instead, we simply report the
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takes the ﬁnal decision on whether or not to pursue that
speciﬁc target. Indeed, according to our criterion for novelty
(E value\1, alignment extending on at least 25% of the
target TM region, see ‘‘Methods’’ for more details), 14 (or
40%) of our nominated seeds have signiﬁcant sequence
similarity to a least one PDB protein. There are various
reasons why nominated targets are sometimes selected dis-
regarding similarity to PDB proteins. Technology develop-
ment projects often need to work on well-characterized test
cases. One such example was the nomination of the KcsA
channel [58] by the solid state NMR group. Also, there are
cases in which sequence similarity as detected by our auto-
matic protocol may not capture important structural and/or
functional differences between the nominated seed and
protein(s) already in the PDB. These differences may mean
that the seed is a very valuable target, notwithstanding the
presence of a homolog in the PDB. Again, this type of
evaluation is left to the nominating group. Another proce-
dural difference between nomination and central selection
pertains to redundancy: nominated seeds do not need to be
non-redundant. The same group can nominate seeds that are
so sequence similar that they expand into the same family.
Despite their similarity, they will be processed as separate
seeds by our pipeline (with overlapping members being
assigned to only one of the resulting seed families). If dif-
ferent groups nominate similar seeds though, we ask that
they reach an agreement on how the resulting targets will be
distributed.
Seed expansion
The seed expansion procedure is the same for centrally
selected and nominated targets and it is based on reciprocal
sequence similarity in the predicted TM region between
seed and NYCOMPS98 proteins (Fig. 2). In particular,
given an alignment between a seed and a NYCOMPS98
protein with PSI-BLAST [39] E value\10
-3, we require
that C50% of the residues predicted to be in TMHs in both
proteins are found in the aligned region. The rationale of the
TM region constraint on the alignment is to avoid associ-
ation of a NYCOMSP98 protein to a seed based merely on
the presence of a common water-soluble domain.
Filtering of targets
After a seed is expanded into a family of proteins predicted
to have similar membrane cores, all family members are
subjected to additional ﬁlters. Since these ﬁlters depend on
information that may quickly change, they are best applied
at the moment the targets have to be submitted to the
experimental pipeline rather than when creating the
NYCOMPS98 dataset.
Novelty: exclusion of PDB homologs
The ﬁrst ﬁltering step is meant to ensure that target proteins
provide novel coverage of the protein universe [50]. Again,
this does not apply to nominated targets. We ﬁlter out any
centrally selected target with signiﬁcant similarity in the
predicted TM region to any protein in the PDB. This
excludes all proteins aligning to a PDB protein with PSI-
BLAST E values\1 and for which the alignment extends
over more than 25% of the predicted TM region (‘‘Meth-
ods’’). Note that while our E value cut-off ensures selection
of targets whose TM domains are more novel than the
average domain selected by other PSI high-throughput
consortia [29], we do allow some overall similarity to PDB
proteins to occur. Indeed, while we want to select novel
targets, we do not want to exclude sequences simply based
on the presence of a soluble domain that has a homolog in
the PDB or on the fact that at most 25% of its TM region
can be modeled based on a protein in the PDB. Finally,
note also that our E value cutoff for avoiding similarity to
PDB proteins is stricter (i.e. requires less similarity for
exclusion of a protein) than the one we used, for example,
for seed expansion (E value\1 vs.\10
-3). This reﬂects
our different goals in the two situations. Whereas in seed
expansion we try to minimize the number of false positives
(proteins not evolutionary related to the seed), in the
comparison with PDB proteins we want to minimize the
number of false negatives (in other words, we want to
exclude as many targets related to PDB proteins as possible
even at the cost of excluding a number of targets that are
not in fact related to any PDB protein). We run this PDB
ﬁlter both at the seed and at the single target level. Seeds
with signiﬁcant similarity to a PDB protein are not con-
sidered for further processing. When a seed passes this
ﬁlter, each individual target in the family into which the
Fig. 2 aIMPs similarity criterion. We align sequence a to sequence b
(both aIMPs) using PSI-BLAST [39]. If the alignment has E value
\10
-3 and it extends over C50% of the predicted TM regions of both
proteins, than we consider b similar to a. This criterion is used
throughout the paper to establish similarity between aIMPs, e.g.
similarity between a seed protein and proteins in the NYCOMPS98
dataset
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123seed expands is still subjected to the same ﬁlter and dis-
carded if it matches our criteria for exclusion.
Exclusion of isolated subunits of hetero-oligomeric
complexes
Occasionally, protein subunits that natively are parts of
larger hetero-oligomeric complexes are structurally stable
even when expressed in isolation (e.g. homotetrameric A
subunit cyclic nucleotide-gated ion channels [59]). How-
ever, in general, when expressed in isolation they are
expected to be less likely to yield experimental structures.
Therefore, our second ﬁlter removes all candidates for
which we have evidence that they might constitute indi-
vidual subunits of hetero-oligomeric complexes. Our
identiﬁcation of such subunits mostly relies on information
extracted from EcoCyc [43] and Swiss-Prot [44]. Addi-
tionally, we seek input from our team of experimentalists.
When we ﬁnd evidence that one or more members of a
family may constitute a subunit of a larger hetero-oligo-
meric complex, we usually discard the entire family. The
ﬁnal decision is taken after consulting with our team of
experimental experts. An alternative way to confront such
cases might be to clone and co-express them with all
components of the complex. However, except for a few
special cases (see below), our experimental pipeline is
currently not set up to perform such operations in a high-
throughput manner.
Removal of outliers
As a ﬁnal step, we try to correct for ‘‘inconsistencies’’ in
our families. We usually discard proteins for which the
number of predicted TMHs differs greatly from that of the
seed, as well as, proteins that differ signiﬁcantly in their
length with respect to the seed (‘‘Methods’’). Also, we try
to exclude proteins that align well with the consensus
N-terminus of the family (when any such consensus can be
identiﬁed) but that feature additional N-terminal residues,
because they constitute cases of proteins that may have
been mis-annotated (Fig. S3).
Other NYCOMPS targets
Several NYCOMPS targets were selected according to
other criteria. For instance, biological-theme targets are
individual proteins handled by participating laboratories in
the usual style of hypothesis-driven rather than hypothesis-
generating structural biology. Such targets typically do not
enter our pipeline at any stage. Another set of examples is
constituted by 230 nominated histidine kinase targets that
were hand-picked by one of our participating groups based
on functional annotations. Some of those have\2 predicted
TMHs (either 1 or 0). Additionally, we cloned 18 con-
structs that consist of co-cistronic (i.e. localized in neigh-
boring regions of the genome) subunits of hetero-
oligomeric complexes. This particular set of complexes can
enter the existing experimental pipeline without modiﬁca-
tions, because we can clone the full DNA stretch spanning
the genes of all involved subunits.
Task II: target analysis
NYCOMPS targets diverse in terms of number
of TMHs and length
In the following, we analyze 6,118 targets (from 174 seed
families) that have been submitted to our experimental
pipeline.79%oftheseoriginatedfrom139centrallyselected
seeds;theother21%from35nominatedseeds(completelist
available at www.rostlab.org/punta/NYCOMPS-targets.
txt). NYCOMPS targets are diverse in terms of their
sequences as well as their predicted structural and func-
tional features. First, the targets selected so far sample a
widerangeintermsofsequencelengthandofthenumberof
TMHs (Fig. 3a, b, respectively). Proteins with 4 and 10
predicted TMHs are the most frequent among our selected
targets. Proteins with four predicted TMHs include, for
example,thecentrallyselectedE.coliseedsHtpX,afamily
ofheatshockproteinsthatmayparticipateindegradationof
misfoldedproteins,andKdpD,thesensormemberofatwo-
component signal transduction system responding to
changes in potassium ion concentration. Proteins with 10
predicted TMHs include RhtA, a threonine/homoserine
exporter, and WecH, an O-acetyltransferase (functional
information for these seeds extracted from EcoCyc [43]).
RhtA, in particular, constitutes our largest seed family
comprising 552 proteins (largest by far, the second largest
family has 200 members). This underlines the fact that the
fractionofproteinswithagivennumberofTMHsinourlist
of selected targets does not translate in general into the
frequencyofseedswiththesamenumberofTMHs.Infact,
agivenseedmightgetexpandedintotargetswitha(usually
slightly) different number of predicted TMHsanddifferent
seeds might generate a very different number of targets.
64% of the selected targets are predicted to have the N-
terminusinside,theother36%havetheN-terminusoutside.
In the next paragraphs, we analyze the sequence and
functional diversity of NYCOMPS targets by mapping
them to well-annotated databases such as Pfam [60], the
TCDB [41]a n dU n i P r o t K B[ 44, 49]. Note that excluding
our largest families (such as RhtA) from the analysis
reported hereafter would slightly change the numbers but
lead to the same overall conclusions.
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63% to TCDB proteins
How ‘‘relevant’’ are NYCOMPS targets to the today’s
biology? We try to address this point by mapping our target
list to two manually curated protein databases that carry
functional annotations: the general purpose Pfam-A
domain database [60] and the IMP-speciﬁc TCDB, a
comprehensive database of membrane transport proteins
[41]. Pfam-A families are manually curated from sequence-
based alignments and they often do not span entire struc-
tural domains [46, 47]. This means that the TM region of a
target may align to more than one Pfam-A family and one
or more Pfam-A families may not cover it entirely. On the
other hand, some of the TM regions in our targets do not
represent single structural domains, e.g. the TM region of
2-hydroxycarboxylate transporters [61]. For these reasons,
we evaluate similarity to Pfam-A families in two ways.
First, we calculate the fraction of our targets that align
(HMMER E value\10
-3) to one or more Pfam-A fami-
lies, collectively covering more than half of the target TM
region. This fraction amounts to 81% of all targets (89% of
nominated and 79% of centrally selected targets, respec-
tively; see Table 1 for different E value thresholds and
different fraction of TM region coverage). Second, we
consider only targets for which it exists at least one Pfam-A
family that by itself aligns over more than half of the
predicted TM region. The percentage of targets satisfying
this condition is equal to 70%. Overall, these latter targets
map to 142 different Pfam-A families, offering additional
evidence of NYCOMPS targets diversity at the sequence
level. Finally, since not all Pfam-A families carry a
functional annotation, we additionally calculate the per-
centage of matches after excluding DUFs and UPFs. In this
case, the previous values become 61% (one or more fam-
ilies, Table S2) and 58% (single family).
We next compared our list of selected targets to TCDB
proteins. We found 63% of all targets to have signiﬁcant
similarity (deﬁned as in Fig. 2, ‘‘Methods’’) to at least
one transport protein in TCDB (nominated targets: 91%;
centrally selected targets: 55%). While TCDB classiﬁca-
tion is organized into ﬁve levels, hereafter we considered
only the ﬁrst three, namely: class, subclass and super-
family/family. In particular, we investigated the percentage
of TCDB classes, subclasses and superfamilies/families for
which we could provide a structural model if we deter-
mined one structure for 25–100% of our seed families
(Table 2).
If we solved one structure for each seed family, 12% of
TCDB superfamilies/families distributed over 45% of all
Fig. 3 Diversity of NYCOMPS targets. a Distribution of sequence
lengths. x-axis tick labels represent ranges, e.g. 100 means between 0
and 100 residues. The last bin (1,100) includes all proteins longer than
1,000 residues. b Distribution of number of TMHs predicted by
TMHMM2 in all selected targets
Table 1 Percentage of NYCOMPS selected targets that map to at
least one Pfam-A family
E value\ TM coverage 0.25 0.5 0.75 1.0
\10
-3 88% 81% 68% 25%
\10
-10 81% 75% 62% 24%
\10
-50 42% 41% 35% 16%
Note that if a target matches more than one Pfam-A family (with
HMMER E value lower than the given threshold), TM region cover-
age is calculated as the sum of TM region coverage for the different
families. Example: 81% of our targets match one or more Pfam-A
families with E value(s)\10
-3 and alignment(s) covering at least half
of the target TM region (second row ‘‘\10
-3’’, third column ‘‘0.5’’)
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(considering our criterion for similarity: at least 50% of
their TM region could be modeled). If instead we solved
one structure for every fourth seed family, we could pro-
vide models for 3% of TCDB superfamilies/families dis-
tributed over 25% of all TCDB subclasses. When
considering these numbers one has to take into account that
TCDB also contains beta barrel integral membrane proteins
that we currently do not taken into consideration as targets
for NYCOMPS and that not all membrane proteins are
transporters (i.e. TCDB does not cover the entire universe
of annotated aIMPs).
In conclusion, comparison to Pfam-A (61%) and TCDB
(63%) shows that a little less than two-thirds of our targets
can at least partially be mapped to functionally annotated
proteins found in manually curated public databases. On
the other hand, we also see that achieving a comprehensive
structural coverage of IMP databases such as TCDB will
require scaling-up considerably the number of selected
seeds and targets.
UniProtKB novel leverage provided by NYCOMPS targets
One important aspect of any SG effort is novel leverage,
i.e. the degree to which each experimental structure enables
the generation of comparative models that were not
available prior to its determination [50]. PSI has overall
performed extremely well by this criterion [29]. In the
context of NYCOMPS target selection we estimated the
novel leverage that would result if we obtained structures
for all, or a fraction of, our families. Note that here we
apply a slightly more restrictive criterion for novel leverage
with respect to its original deﬁnition [50], that is, not novel
leverage with respect to the time targets were selected but
novel leverage as of February 2009. We deﬁned the
leverage by aligning all our targets against UniProtKB but
discarding aligned UniProtKB sequences predicted to have
\2 TMHs (we call this subset UniProtKB-TMH).
If we solved one structure for each seed family, we
could model at least 50% of the TM region of *130,000
novel proteins in UniProtKB-TMH (Fig. 4a, blank circles
and full line); if we determined one in every fourth family,
we could still model on the average about 33,000 Uni-
ProtKB proteins (Fig. 4a); ﬁnally, should we solve a
structure for only 10 of the targeted families, we could
model on average close to 8,000 proteins (although for
such a number of solved structures actual coverage would
crucially depend on what these proteins are, see standard
deviation Fig. 4a). Looking at leverage for each family, we
see that about two-thirds of the seed families have over 200
novel UniProtKB-TMH homologs; only 18 families have
novel leverage \50. UniProtKB is an ever-increasing
database of annotated protein sequences (mostly open
reading frames). As the number of sequenced proteins and
organisms increases, UniProtKB-TMH leverage for a given
set of targets will also increase. This means that the naked
numbers we just reported may not be very meaningful. In
other words, while it is true that we can model a large
number of proteins if we solve the structure of at least some
of the NYCOMPS targets, it is also true that this may
simply reﬂect the sheer size of UniProtKB and the fact that,
as more data become available, proteins cluster into
increasingly large homologous families. For this reason it
is probably more interesting to compare our projected
UniProtKB-TMH leverage with the UniProtKB-TMH
leverage obtained by using a non-redundant set of PDB
proteins predicted to have C2 TMHs (187 proteins total,
see ‘‘Methods’’). This is a more direct measure of the
impact NYCOMPS could have on our knowledge of the
aIMPs structural universe. To identify PDB aIMPs we use
predictions instead of annotations to be consistent with the
way we picked our targets and with the way we identiﬁed
aIMPs in UniProtKB. If we do this (Fig. 4b), we see that
while solving one structure for each of our selected seeds
would provide novel leverage equal to about 43% of what
currently possible with available structures, solving only 10
structures would provide leverage equal to 2 to 3% of what
is already possible.
Next, we investigated the leverage with respect to Swiss-
Prot-TMH, i.e. the manually annotated subset of Uni-
ProtKB-TMH (Fig. 4a, ﬁlled diamonds and long-dashes). In
this case, NYCOMPStargets wouldallow to modelbetween
300 and 4,700 novel Swiss-Prot-TMH proteins, depending
on the number of seed families for which we can solve at
least one structure. The fraction of novel leverage with
respect to what currently possible using PDB proteins fol-
lows a very similar trend with respect to what seen for the
entire UniProtKB-TMH (Fig. 4b).
Table 2 Target leverage: TCDB
Fraction of target
families solved out
of 174
TCDB
Level
1 (7) (%)
TCDB Level
2 (24) (%)
TCDB Level
3 (557) (%)
18 6 ±04 5 ±21 2 ±0
0.75 82±64 0 ±49 ±1
0.50 77±83 5 ±57 ±1
0.25 66±11 25±53 ±0
We run PSI-BLAST against all proteins in TCDB using all our targets
as queries. We then use bootstrapping to calculate the percentage of
TCDB classiﬁcation numbers we could provide a structural model for
(leverage) if we solved one target per each seed family (‘‘Methods’’).
This is done for the ﬁrst three levels in the TCDB classiﬁcation.
Levels 1–3 correspond to class, subclass, superfamily/family.
Example: if we solved a structure for each one of our seed families,
we could provide a structural model for at least one protein in 45% of
the 24 TCDB subclasses (second row ‘‘1’’, third column ‘‘TCDB
Level 2 (24)’’)
Target selection for integral membrane proteins 265
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UniProtKB-TMH, we ﬁnd that novel structural information
could be obtained for 10–260 proteins (Fig. 4a, crossed
squares and short-dash line). This time, the ratio to current
leverage is markedly smaller (Fig. 4b). This is not very
surprising given that all of our targets come from pro-
karyotic organisms.
Conclusions
New York Consortium On Membrane Protein Structure
(NYCOMPS), targets alpha helical bundle integral mem-
brane proteins, adopting a strategy that seeks to optimize
success while maintaining the commitment to novelty,
target relevance and leverage. In this paper, we have shown
that the selected targets cover a wide range of protein
lengths, TM topologies and functions. We have also
demonstrated that the experimental determination of rep-
resentative structures for these targets would allow transfer
of structural information to a large number of known, but
structurally uncharacterized, proteins. In the near future,
we plan to expand the list of valid targets by introducing
new genomes and by targeting eukaryotic proteins, non-co-
cistronic complexes and beta barrel integral membrane
proteins.
Acknowledgments This work was supported by the grant U54-
GM75026-01 to the NYCOMPS from PSI of the NIH. Thanks to all
NYCOMPS collaborators who contribute to making NYCOMPS a
wonderful experience, in particular thanks to Ann McDermott,
Filippo Mancia, Ming Zhou, Francesca Gubellini (all Columbia),
Da-Neng Wang (New York University), Mark Girvin (Albert Einstein),
Guy Montelione (Rutgers), Renato Bruni and Brian Kloss (both
NYCOMPS). Speciﬁc thanks to Jinfeng Liu (Genentech), Jessica
Locke (Rutgers) and Rajesh Nair (Food and Drug Administration) for
providing preliminary information and programs; to Ta-tsen Soong
(Columbia), Henry Bigelow and Dariusz Przybylski (both Broad
Institute), Kaz Wrzeszczynski (Cold Spring Harbor Laboratory),
Zsuzsanna Dosztanyi (Hungarian Academy of Sciences, Budapest)
and Zsolt Zolnai (University of Wisconsin—Madison) for useful
discussions; to Guy Yachdav and Laszlo Kajan (both Columbia) for
computer assistance and the collection of genome data sets. Last, not
least, thanks to all those who deposit their experimental data in public
databases, and to those who maintain these databases.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Burley SK, Joachimiak A, Montelione GT, Wilson IA (2008)
Contributions to the NIH-NIGMS protein structure initiative from
the PSI production centers. Structure 16:5–11
Fig. 4 Potential novel aIMP leverage provided by NYCOMPS
targets. a The x-axis gives the number of seed families for which
we hypothetically determine a structure (corresponding to 10 seed
families or to 25–100% of all seed families; e.g. 25% corresponds to
43 seed families and 100% to 174 seed families); the y-axis reports
the number of predicted aIMPs with more than 2 TMHs for which
more than 50% of the residues in the TM region could be modeled
using the NYCOMPS targets on the x-axis as templates (leverage).
Numbers on the y-axis are for proteins in: UniProtKB-TMH (i.e. all
predicted aIMPs in UniProtKB with more than 2 TMHs, see
‘‘Methods’’; blank circles and continuous line), Swiss-Prot-TMH
(ﬁlled diamonds and long-dash line) and UniProtKB-TMH-Human
(i.e. human proteins in UniProtKB-TMH, crossed squares and short-
dash line). Error bars are obtained by bootstrapping [48]( ‘‘Meth-
ods’’). b Comparison between NYCOMPS target and PDB protein
leverage. On the y-axis we report the ratio between the respective
leverage values. Notations are as in (a). See ‘‘Methods’’ for the way
UniProtKB-TMH leverage by PDB proteins is calculated
266 M. Punta et al.
1232. Norvell JC, Berg JM (2007) Update on the protein structure
initiative. Structure 15:1519–1522
3. Norvell JC, Machalek AZ (2000) Structural genomics programs
at the US national institute of general medical sciences. Nat
Struct Biol 7 Suppl:931
4. Stroud RM, Choe S, Holton J, Kaback HR, Kwiatkowski W,
Minor DL, Riek R, Sali A, Stahlberg H, Harries W (2009) 2007
Annual progress report synopsis of the center for structures of
membrane proteins. J Struct Funct Genomics 10:193–208
5. PuntaM,ForrestLR,BigelowH,KernytskyA,LiuJ,RostB(2007)
Membrane protein prediction methods. Methods 41:460–474
6. von Heijne G (2007) The membrane protein universe: what’s out
there and why bother? J Intern Med 261:543–557
7. Knight CG, Kassen R, Hebestreit H, Rainey PB (2004) Global
analysis of predicted proteomes: functional adaptation of physical
properties. Proc Natl Acad Sci U S A 101:8390–8395
8. Liu J, Rost B (2001) Comparing function and structure between
entire proteomes. Protein Sci 10:1970–1979
9. Bigelow H, Petrey D, Liu J, Przybylski D, Rost B (2004) Pre-
dicting transmembrane beta-barrels in proteomes. Nucleic Acids
Res 32:2566–2577
10. Bigelow H, Rost B (2006) PROFtmb: a web server for predicting
bacterial transmembrane beta barrel proteins. Nucleic Acids Res
34:W186–W188
11. Wimley WC (2003) The versatile beta-barrel membrane protein.
Curr Opin Struct Biol 13:404–411
12. Bigelow H, Rost B (2009) Online tools for predicting integral
membrane proteins. Methods Mol Biol 528:3–23
13. Dong C, Beis K, Nesper J, Brunkan-Lamontagne AL, Clarke BR,
Whitﬁeld C, Naismith JH (2006) Wza the translocon for E. coli
capsular polysaccharides deﬁnes a new class of membrane pro-
tein. Nature 444:226–229
14. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many
drug targets are there? Nat Rev Drug Discov 5:993–996
15. Carpenter EP, Beis K, Cameron AD, Iwata S (2008) Overcoming
the challenges of membrane protein crystallography. Curr Opin
Struct Biol 18:581–586
16. Wang G (2008) NMR of membrane-associated peptides and
proteins. Curr Protein Pept Sci 9:50–69
17. Wiener MC (2004) A pedestrian guide to membrane protein
crystallization. Methods 34:364–372
18. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE,
Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, Fagan P,
Marvin J, Padilla D, Ravichandran V, Schneider B, Thanki N,
Weissig H, Westbrook JD, Zardecki C (2002) The protein data
bank. Acta Crystallogr D Biol Crystallogr 58:899–907
19. White SH (2004) The progress of membrane protein structure
determination. Protein Sci 13:1948–1949
20. Wagner S, Baars L, Ytterberg AJ, Klussmeier A, Wagner CS,
Nord O, Nygren PA, van Wijk KJ, de Gier JW (2007) Conse-
quences of membrane protein overexpression in Escherichia coli.
Mol Cell Proteomics 6:1527–1550
21. Chen CP, Rost B (2002) Long membrane helices and short loops
predicted less accurately. Protein Sci 11:2766–2773
22. von Heijne G (1994) Membrane proteins: from sequence to
structure. Annu Rev Biophys Biomol Struct 23:167–192
23. Eshaghi S (2009) High-throughput expression and detergent
screening of integral membrane proteins. Methods Mol Biol
498:265–271
24. Gutmann DA, Mizohata E, Newstead S, Ferrandon S, Postis V, Xia
X,HendersonPJ,vanVeenHW,ByrneB(2007)Ahigh-throughput
method for membrane protein solubility screening: the ultracentri-
fugation dispersity sedimentation assay. Protein Sci 16:1422–1428
25. Liu J, Hegyi H, Acton TB, Montelione GT, Rost B (2004)
Automatic target selection for structural genomics on eukaryotes.
Proteins 56:188–200
26. Montelione GT, Anderson S (1999) Structural genomics: key-
stone for a human proteome project. Nat Struct Biol 6:11–12
27. Rost B (1998) Marrying structure and genomics. Structure 6:
259–263
28. Forrest LR, Tang CL, Honig B (2006) On the accuracy of
homology modeling and sequence alignment methods applied to
membrane proteins. Biophys J 91:508–517
29. Nair R, Liu J, Soong TT, Acton TB, Everett JK, Kouranov A,
Fiser A, Godzik A, Jaroszewski L, Orengo C, Montelione GT,
Rost B (2009) Structural genomics is the largest contributor of
novel structural leverage. J Struct Funct Genomics 10:181–191
30. Pruitt KD, Tatusova T, Maglott DR (2007) NCBI reference
sequences (RefSeq): a curated non-redundant sequence database of
genomes, transcripts and proteins. Nucleic Acids Res 35:D61–D65
31. Krogh A, Larsson B, von Heijne G, Sonnhammer EL (2001) Pre-
dicting transmembrane protein topology with a hidden Markov
model: application to complete genomes. J Mol Biol 305:567–580
32. Chen CP, Kernytsky A, Rost B (2002) Transmembrane helix
predictions revisited. Protein Sci 11:2774–2791
33. Cuthbertson JM, Doyle DA, Sansom MS (2005) Transmembrane
helix prediction: a comparative evaluation and analysis. Protein
Eng Des Sel 18:295–308
34. Li W, Godzik A (2006) Cd-hit: a fast program for clustering and
comparing large sets of protein or nucleotide sequences. Bioin-
formatics 22:1658–1659
35. Emanuelsson O, Brunak S, von Heijne G, Nielsen H (2007)
Locating proteins in the cell using TargetP, SignalP and related
tools. Nat Protoc 2:953–971
36. Dosztanyi Z, Csizmok V, Tompa P, Simon I (2005) The pairwise
energy content estimated from amino acid composition discrim-
inates between folded and intrinsically unstructured proteins. J
Mol Biol 347:827–839
37. Schlessinger A, Punta M, Rost B (2007) Natively unstructured
regions in proteins identiﬁed from contact predictions. Bioinfor-
matics 23:2376–2384
38. Schlessinger A, Punta M, Yachdav G, Kajan L, Rost B (2009)
Improved disorder prediction by combination of orthogonal
approaches. PLoS One 4:e4433
39. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller
W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new
generation of protein database search programs. Nucleic Acids
Res 25:3389–3402
40. UniProt (2009) The universal protein resource (UniProt) 2009.
Nucleic Acids Res 37:D169–D174
41. Saier MH Jr, Tran CV, Barabote RD (2006) TCDB: the trans-
porter classiﬁcation database for membrane transport protein
analyses and information. Nucleic Acids Res 34:D181–D186
42. Liu J, Rost B (2004) CHOP proteins into structural domain-like
fragments. Proteins 55:678–688
43. Keseler IM, Bonavides-Martinez C, Collado-Vides J, Gama-
Castro S, Gunsalus RP, Johnson DA, Krummenacker M, Nolan
LM, Paley S, Paulsen IT, Peralta-Gil M, Santos-Zavaleta A,
Shearer AG, Karp PD (2009) EcoCyc: a comprehensive view of
Escherichia coli biology. Nucleic Acids Res 37:D464–D470
44. Bairoch A, Apweiler R, Wu CH, Barker WC, Boeckmann B,
Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ,
Natale DA, O’Donovan C, Redaschi N and Yeh LS (2005) The
universal protein resource (UniProt), Nucleic Acids Res,3 3
Database Issue, D154–D159
45. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W:
improvingthesensitivityofprogressivemultiplesequencealignment
through sequence weighting, position-speciﬁc gap penalties and
weight matrix choice. Nucleic Acids Res 22:4673–4680
46. FinnRD,TateJ,MistryJ,CoggillPC,SammutSJ,HotzHR,CericG,
Forslund K, Eddy SR, Sonnhammer EL, Bateman A (2008) The
Pfam protein families database. Nucleic Acids Res 36:D281–D288
Target selection for integral membrane proteins 267
12347. Liu J, Rost B (2003) Domains, motifs, and clusters in the protein
universe. Curr Opin Chem Biol 7:5–11
48. Efron B, Tibshirani RJ (1993) An introduction to the bootstrap.
Chapman & Hall/CRC, Boca Raton
49. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B,
Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ,
Natale DA, O’Donovan C, Redaschi N, Yeh LS (2004) UniProt:
the universal protein knowledgebase. Nucleic Acids Res
32:D115–D119
50. Liu J, Montelione GT, Rost B (2007) Novel leverage of structural
genomics. Nat Biotechnol 25:849–851
51. Acton TB, Gunsalus KC, Xiao R, Ma LC, Aramini J, Baran MC,
Chiang YW, Climent T, Cooper B, Denissova NG, Douglas SM,
Everett JK, Ho CK, Macapagal D, Rajan PK, Shastry R, Shih LY,
Swapna GV, Wilson M, Wu M, Gerstein M, Inouye M, Hunt JF,
Montelione GT (2005) Robotic cloning and protein production
platform of the northeast structural genomics consortium. Meth-
ods Enzymol 394:210–243
52. Sauder MJ, Rutter ME, Bain K, Rooney I, Gheyi T, Atwell S,
Thompson DA, Emtage S, Burley SK (2008) High throughput
protein production and crystallization at NYSGXRC. Methods
Mol Biol 426:561–575
53. Moller S, Croning MD, Apweiler R (2001) Evaluation of meth-
ods for the prediction of membrane spanning regions. Bioinfor-
matics 17:646–653
54. Jaroszewski L, Slabinski L, Wooley J, Deacon AM, Lesley SA,
Wilson IA, Godzik A (2008) Genome pool strategy for structural
coverage of protein families. Structure 16:1659–1667
55. EsnoufRM,HamerR,SussmanJL,SilmanI,TrudgianD,YangZR,
Prilusky J (2006) Honing the in silico toolkit for detecting protein
disorder. Acta Crystallogr D Biol Crystallogr 62:1260–1266
56. Daley DO, Rapp M, Granseth E, Melen K, Drew D, von Heijne G
(2005) Global topology analysis of the Escherichia coli inner
membrane proteome. Science 308:1321–1323
57. Drew D, Slotboom DJ, Friso G, Reda T, Genevaux P, Rapp M,
Meindl-Beinker NM, Lambert W, Lerch M, Daley DO, Van Wijk
KJ, Hirst J, Kunji E, De Gier JW (2005) A scalable, GFP-based
pipeline for membrane protein overexpression screening and
puriﬁcation. Protein Sci 14:2011–2017
58. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM,
Cohen SL, Chait BT, MacKinnon R (1998) The structure of the
potassium channel: molecular basis of K? conduction and
selectivity. Science 280:69–77
59. Biel M (2009) Cyclic nucleotide-regulated cation channels. J Biol
Chem 284:9017–9021
60. Bateman A, Coin L, Durbin R, Finn RD, Hollich V, Grifﬁths-
Jones S, Khanna A, Marshall M, Moxon S, Sonnhammer EL,
Studholme DJ, Yeats C, Eddy SR (2004) The Pfam protein
families database. Nucleic Acids Res 32:D138–D141
61. Lolkema JS (2006) Domain structure and pore loops in the
2-hydroxycarboxylate transporter family. J Mol Microbiol Bio-
technol 11:318–325
268 M. Punta et al.
123